The FDA recently cleared Freeline Therapeutics to begin treating patients in the United States.
Interim data from an ongoing study demonstrate continuing efficacy in B-NHL, CLL, and FL.
The new, 2-year data is from a roll-in cohort of 10 patients presented at the HFSA 2022 meeting.
Karen Walker, chief technology officer, Kyverna Therapeutics, discussed the company’s CAR T-cell and regulatory T-cell technologies.
Significant improvements were reported in full-field stimulus testing.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.